Parkinson DiseaseNCT04019158
Effects of iVR Treadmill on Gait in PD
A study testing Virtual reality headset in people with Parkinson Disease and Virtual Reality, run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain at 1 site in Belgium.
Trial summary
Parkinson's Disease (PD) patients suffer from gait impairments responsible for falls and bad quality of life: reduced speed and stride length, randomness in stride duration variability (reduced Long-Range Autocorrelations (LRA)). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Parkinson Disease, Virtual Reality, Gait Disorders, Neurologic
- What is being tested?
- Virtual reality headset
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteBelgium
- Study dates
- 10 Apr 2019to 19 Sep 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- PD patients:
- idiopathic PD diagnosis made by an experienced neurologist according to United Kingdom Brain Bank criteria
- mild to moderate motor disorders according to modified Hoehn \& Yahr scale (stages I-III)
- ability to walk for a minimum of 512 gait cycles (±15 minutes) in a row without walking aids
- no other pathology interacting with gait or provoking dizziness
- no uncorrected vision disorders
- a minimum of 24/30 on the Mini-Mental State Examination (MMSE)
Who cannot join
- PD Patients:
- other neurological or orthopedic pathologies that could interact with their motor capacities and gait performance
- pathology that could provoke vertigo or nausea
- uncorrected vision disorders
- contraindications to physical exercise
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Immersive Virtual Reality on Treadmill to Ecologically Assess Parkinson's Disease Patients' Gait
Parkinson's Disease (PD) patients suffer from gait impairments responsible for falls and bad quality of life: reduced speed and stride length, randomness in stride duration variability (reduced Long-Range Autocorrelations (LRA)). This pilot study will compare the spatio-temporal walking parameters and LRA of PD patients tested under three conditions: walking over ground, walking on a treadmill and walking on a treadmill in virtual reality. The aim is to determine the effect on gait of an optical flow recreated in virtual reality, by means of a virtual reality headset, on a treadmill.
Read the detailed description
- BACKGROUND Parkinson's disease (PD) is the second most common degenerative neurological disease. PD induces gait disorders that lead to increased risk of falls. These falls seriously affect patients' quality of life and generate significant health care costs. Unfortunately, gait disorders do not respond well to drug treatments and their management is mainly based on rehabilitation treatment. The rehabilitation approach comprises two steps: a functional assessment of locomotor capacities followed by completion of a therapeutic physical exercise program. Like heart rate, stride duration varies in the short and long term according to a complex dynamic of temporal variations. These variations present long-range autocorrelations (LRA): the stride duration does not vary randomly but in a structured way. The study of LRA is based on complex mathematical methods requiring recording of 512 consecutive gait cycles. LRA are altered in PD patients whose gait rhythm is excessively random. Alteration of LRA is correlated with neurological impairments (Hoehn \& Yahr scale and UPDRS) and patients' locomotor stability (ABC scale \& BESTest). Measurement of LRA would be the first available objective and quantitative biomarker of stability and risk of falling in patients with PD. Guidelines concerning rehabilitation programs for PD patients are based on education (prevention of falls and inactivity,...), physical exercises, functional training (double task, complex tasks,...), learning, adaptation strategies (cueing) and action observation. The combination between immersive virtual reality (iVR), using an iVR headset, and treadmill walking will be developped. Treadmill walking has shown long-term effectiveness on PD patients' gait and quality of life. A study carried out recently has shown that a single treadmill session reduces the stride duration variability during the intervention. Although the treadmill seems to improve patients' gait, it lacks an essential ecological component that allows humans to stabilize gait: an optical flow, an environment that scrolls during walking. iVR allows to give patients a visual flow when walking on treadmill as if they were walking overground and patients could benefit from it. The purpose of this pilot study is to compare the spatio-temporal gait parameters and gait variability parameters obtained during three Walking conditions: over ground walking, treadmill walking, treadmill walking with a VR headset.
- METHODS
2.1 Participants : 10 patients suffering from idiopathic Parkinson's Disease will be recruited from the local community and from the Neurology and the Physical and Rehabilitation Medicine outpatient clinics of the Cliniques universitaires Saint-Luc (Woluwe-Saint-Lambert, Belgium).
2.2 Functional assessment: Before the expermientations starts, all participants will undergo a non harmful assessment including clinical tests and questionnaires
PD patients: Age, height, weight, sex, most affected side, Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS), Mini Balance Evaluation Systems Test (Mini-BESTest), Simplified version of the Activities-specific Balance Confidence Scale (ABC-Scale), modified Hoehn \& Yahr scale, Mini Mental State Examination (MMSE).
2.3 Procedure : Every participants will walk in three conditions in a randomized order. Each condition lasted ±15 minutes in order to get 512 gait cycles mandatory to assess the presence of LRA.
The first condition consists in Over ground Walking (OW). Participants will be asked to walk on an rectangular track with rounded corner of 63.2 meters in CUSL at their comfortable walking speed.
The second condition is Treadmill Walking (TW). Patients will walk on the treadmill at their comfortable walking speed assessed before the condition with a 10 Meter Walk Test. During this condition, patients will wear a non weight-bearing safety harness (Petzl, Volt, France).
The last condition consists in walking on a treadmill, at the same speed as during TW, patients still wearing the non weight-bearing harness, while wearing a VR headset (VRTW). The VR headset (HTC, Vive, Taïwan) consists of a kind of mask that the person comes to put on his face. Two Fresnel lenses are in front of the person's eyes and the person looks at a display that allows stereoscopic 3D through these lenses. The patient is then immersed in an immersive virtual environment, cut off from the outside world. For this experiment, a VR environment has been created by means of Unity software and using C# code. While walking on the treadmill, the participants will see a quiet hallway surrounding them. The participants will perceive an optic flow while walking on the treadmill. The speed of the optic flow perceived inside the headset by the patient will be matched with the speed of the treadmill to create the illusion of walking on an actual hallway. A cybersickness questionnaire (Simulator Sickness Questionnaire, SSQ) will be completed before and just after VRTW. Indeed, the use of a VR headset can cause dizziness, nausea, headaches and other symptoms in some patients. We want to evaluate whether or not the use of an optical flow displayed in VR on a treadmill leads to cybersickness.
2.4 Data acquisition: Two Inertial Measurement Units (IMU) (IMeasureU Research, VICON, USA) will be taped on patients' both lateral malleoli. IMUs will be taped on the leg on the side most affected by the disease. This system allowed to record ankle accelerations at 500 Hz. The data will then be put on a computer and each peak of acceleration, corresponding to each heel strike, will be detected by software internally developed to determine all stride durations.
2.5 Gait assessment: Data will be extracted from 512 consecutive gait cycles which is required to measure gait variability.
2.5.1 Spatiotemporal gait variables:
Mean gait speed, gait cadence and stride length will be measured as follow:
Mean gait speed (m.s-1) = Total walking distance (m)/ Acquisition duration (s) Gait cadence (#steps.min-1) = Total number of steps (#)/Acquisition duration (min) Step length (m) = Gait speed (m/s)*60/Gait cadence (steps/min)
2.5.2 Stride duration variability : Stride duration variability can be assessed 2 ways: in terms of magnitude or in terms of organization (how stride duration evolves across consecutive gait cycles).
2.5.2.1 Magnitude of the stride duration variability : To determine the effect of the RAS on the magnitude of the stride duration variability during 512 gait cycles, the mean, the standard deviation (SD) and the coefficient of variation (CV = [SD/mean] * 100) will be assessed.
2.5.2.2 Temporal organization of the stride duration variability (LRA) : Temporal organization of stride duration variability will be assessed by LRA computation using the evenly spaced averaged version of the Detrended Fluctuation Analysis (DFA) to obtain α exponent. The presence of LRA can be shown with α exponent values between 0.5 and 1.
Data will be treated by the mean of CVI Labwindows (C++).
2.6 Statistical analyses : Statistical analyses will be conducted using Sigmaplot 13. If the normality test is passed, a one-way repeated measures ANOVA will be applied to determine the effect of the various walking condition on spatiotemporal gait parameters (gait speed, gait cadence, stride length) and on linear and nonlinear measures of stride duration variability (CV, SD, H and α exponents). When a significant difference between groups is detected with the ANOVA, a post hoc test will be performed to compare each mean with the other means to isolate the groups from each other.
A paired t-test will also be conducted to determine a possible change in score on the SSQ questionnaire after TW and after VRTW.
- Conditions
- Parkinson Disease, Virtual Reality, Gait Disorders, Neurologic, Long Range Autocorrelations
- Being tested
- Virtual reality headset
- Keywords
- Parkinson's Disease, Virtual reality, Gait, Variability, Fractal
- Medical subject headings
- Parkinson Disease, Gait Disorders, Neurologic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual reality headsetDevice
All participants will walk in the three conditions described earlier in this form
| Study group | Role | What they receive |
|---|---|---|
| Parkinson's Disease patients | Experimental | Parkinson's Disease patients will walk in three conditions for +- 15 minutes per condition: walking over ground, walking on a treadmill, walking on a treadmill in virtual reality Receives: Device: Virtual reality headset |
What is being measured
The primary outcome is the main question the study is designed to answer.
Long-Range Autocorrelations
Long-Range Autocorrelations
Measured: Change from baseline in long-range autocorrelations during each intervention condition (3 x 10 min walking)
Secondary outcomes (5)
Mean gait speed
Total walking distance (m)/ Acquisition duration (s)
Measured: Change from baseline in mean gait speed during each intervention condition (3 x 10 min walking)
Step length
Gait speed (m/s)*60/Gait cadence (steps/min)
Measured: Change from baseline in step length during each intervention condition (3 x 10 min walking)
Gait cadence
Total number of steps (#)/Acquisition duration (min)
Measured: Change from baseline in gait cadence during each intervention condition (3 x 10 min walking)
Coefficient of variation of stride duration
[SD/mean stride duration] * 100
Measured: Change from baseline in coefficient of variation during each intervention condition (3 x 10 min walking)
Simulator Sickness Questionnaire (SSQ)
It is a questionnaire about symptoms that may appear when using virtual reality headsets
Measured: Change from baseline in SSQ after the VRW condition
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2019
- Study start10 Apr 2019
- Primary completion19 Sep 2019
- Study completion19 Sep 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by Cliniques universitaires Saint-Luc- Université Catholique de LouvainThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Thierry Lejeune, PhD, Principal investigator, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04019158
- Sponsor's protocol ID
- NMSK - Lheureux 02
- Status last verified
- May 2020
- First submitted
- 9 May 2019
- Last updated
- 6 May 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Immersive Virtual Reality on Treadmill to Ecologically Assess Parkinson's Disease Patients' Gait
- ClinicalTrials.gov ID
- NCT04019158
- Acronym / sponsor ID
- NMSK - Lheureux 02
- Conditions
- Parkinson Disease, Virtual Reality, Gait Disorders, Neurologic, Long Range Autocorrelations
- Keywords
- Parkinson's Disease, Virtual reality, Gait, Variability, Fractal
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de LouvainUniversity, hospital or other
- Study start
- 10 Apr 2019 (actual)
- Primary completion
- 19 Sep 2019 (actual)
- Study completion
- 19 Sep 2019 (actual)
- First posted
- 15 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Parkinson's Disease (PD) patients suffer from gait impairments responsible for falls and bad quality of life: reduced speed and stride length, randomness in stride duration variability (reduced Long-Range Autocorrelations (LRA)). This pilot study will compare the spatio-temporal walking parameters and LRA of PD patients tested under three conditions: walking over ground, walking on a treadmill and walking on a treadmill in virtual reality. The aim is to determine the effect on gait of an optical flow recreated in virtual reality, by means of a virtual reality headset, on a treadmill.
Detailed description
- BACKGROUND Parkinson's disease (PD) is the second most common degenerative neurological disease. PD induces gait disorders that lead to increased risk of falls. These falls seriously affect patients' quality of life and generate significant health care costs. Unfortunately, gait disorders do not respond well to drug treatments and their management is mainly based on rehabilitation treatment. The rehabilitation approach comprises two steps: a functional assessment of locomotor capacities followed by completion of a therapeutic physical exercise program. Like heart rate, stride duration varies in the short and long term according to a complex dynamic of temporal variations. These variations present long-range autocorrelations (LRA): the stride duration does not vary randomly but in a structured way. The study of LRA is based on complex mathematical methods requiring recording of 512 consecutive gait cycles. LRA are altered in PD patients whose gait rhythm is excessively random. Alteration of LRA is correlated with neurological impairments (Hoehn \& Yahr scale and UPDRS) and patients' locomotor stability (ABC scale \& BESTest). Measurement of LRA would be the first available objective and quantitative biomarker of stability and risk of falling in patients with PD. Guidelines concerning rehabilitation programs for PD patients are based on education (prevention of falls and inactivity,...), physical exercises, functional training (double task, complex tasks,...), learning, adaptation strategies (cueing) and action observation. The combination between immersive virtual reality (iVR), using an iVR headset, and treadmill walking will be developped. Treadmill walking has shown long-term effectiveness on PD patients' gait and quality of life. A study carried out recently has shown that a single treadmill session reduces the stride duration variability during the intervention. Although the treadmill seems to improve patients' gait, it lacks an essential ecological component that allows humans to stabilize gait: an optical flow, an environment that scrolls during walking. iVR allows to give patients a visual flow when walking on treadmill as if they were walking overground and patients could benefit from it. The purpose of this pilot study is to compare the spatio-temporal gait parameters and gait variability parameters obtained during three Walking conditions: over ground walking, treadmill walking, treadmill walking with a VR headset.
- METHODS
2.1 Participants : 10 patients suffering from idiopathic Parkinson's Disease will be recruited from the local community and from the Neurology and the Physical and Rehabilitation Medicine outpatient clinics of the Cliniques universitaires Saint-Luc (Woluwe-Saint-Lambert, Belgium).
2.2 Functional assessment: Before the expermientations starts, all participants will undergo a non harmful assessment including clinical tests and questionnaires
PD patients: Age, height, weight, sex, most affected side, Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS), Mini Balance Evaluation Systems Test (Mini-BESTest), Simplified version of the Activities-specific Balance Confidence Scale (ABC-Scale), modified Hoehn \& Yahr scale, Mini Mental State Examination (MMSE).
2.3 Procedure : Every participants will walk in three conditions in a randomized order. Each condition lasted ±15 minutes in order to get 512 gait cycles mandatory to assess the presence of LRA.
The first condition consists in Over ground Walking (OW). Participants will be asked to walk on an rectangular track with rounded corner of 63.2 meters in CUSL at their comfortable walking speed.
The second condition is Treadmill Walking (TW). Patients will walk on the treadmill at their comfortable walking speed assessed before the condition with a 10 Meter Walk Test. During this condition, patients will wear a non weight-bearing safety harness (Petzl, Volt, France).
The last condition consists in walking on a treadmill, at the same speed as during TW, patients still wearing the non weight-bearing harness, while wearing a VR headset (VRTW). The VR headset (HTC, Vive, Taïwan) consists of a kind of mask that the person comes to put on his face. Two Fresnel lenses are in front of the person's eyes and the person looks at a display that allows stereoscopic 3D through these lenses. The patient is then immersed in an immersive virtual environment, cut off from the outside world. For this experiment, a VR environment has been created by means of Unity software and using C# code. While walking on the treadmill, the participants will see a quiet hallway surrounding them. The participants will perceive an optic flow while walking on the treadmill. The speed of the optic flow perceived inside the headset by the patient will be matched with the speed of the treadmill to create the illusion of walking on an actual hallway. A cybersickness questionnaire (Simulator Sickness Questionnaire, SSQ) will be completed before and just after VRTW. Indeed, the use of a VR headset can cause dizziness, nausea, headaches and other symptoms in some patients. We want to evaluate whether or not the use of an optical flow displayed in VR on a treadmill leads to cybersickness.
2.4 Data acquisition: Two Inertial Measurement Units (IMU) (IMeasureU Research, VICON, USA) will be taped on patients' both lateral malleoli. IMUs will be taped on the leg on the side most affected by the disease. This system allowed to record ankle accelerations at 500 Hz. The data will then be put on a computer and each peak of acceleration, corresponding to each heel strike, will be detected by software internally developed to determine all stride durations.
2.5 Gait assessment: Data will be extracted from 512 consecutive gait cycles which is required to measure gait variability.
2.5.1 Spatiotemporal gait variables:
Mean gait speed, gait cadence and stride length will be measured as follow:
Mean gait speed (m.s-1) = Total walking distance (m)/ Acquisition duration (s) Gait cadence (#steps.min-1) = Total number of steps (#)/Acquisition duration (min) Step length (m) = Gait speed (m/s)*60/Gait cadence (steps/min)
2.5.2 Stride duration variability : Stride duration variability can be assessed 2 ways: in terms of magnitude or in terms of organization (how stride duration evolves across consecutive gait cycles).
2.5.2.1 Magnitude of the stride duration variability : To determine the effect of the RAS on the magnitude of the stride duration variability during 512 gait cycles, the mean, the standard deviation (SD) and the coefficient of variation (CV = [SD/mean] * 100) will be assessed.
2.5.2.2 Temporal organization of the stride duration variability (LRA) : Temporal organization of stride duration variability will be assessed by LRA computation using the evenly spaced averaged version of the Detrended Fluctuation Analysis (DFA) to obtain α exponent. The presence of LRA can be shown with α exponent values between 0.5 and 1.
Data will be treated by the mean of CVI Labwindows (C++).
2.6 Statistical analyses : Statistical analyses will be conducted using Sigmaplot 13. If the normality test is passed, a one-way repeated measures ANOVA will be applied to determine the effect of the various walking condition on spatiotemporal gait parameters (gait speed, gait cadence, stride length) and on linear and nonlinear measures of stride duration variability (CV, SD, H and α exponents). When a significant difference between groups is detected with the ANOVA, a post hoc test will be performed to compare each mean with the other means to isolate the groups from each other.
A paired t-test will also be conducted to determine a possible change in score on the SSQ questionnaire after TW and after VRTW.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Parkinson's Disease patients | Experimental | Device: Virtual reality headsetParkinson's Disease patients will walk in three conditions for +- 15 minutes per condition: walking over ground, walking on a treadmill, walking on a treadmill in virtual reality |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
- idiopathic PD diagnosis made by an experienced neurologist according to United Kingdom Brain Bank criteria
- mild to moderate motor disorders according to modified Hoehn \& Yahr scale (stages I-III)
- ability to walk for a minimum of 512 gait cycles (±15 minutes) in a row without walking aids
- no other pathology interacting with gait or provoking dizziness
- no uncorrected vision disorders
Key exclusion criteria (5 listed)
- other neurological or orthopedic pathologies that could interact with their motor capacities and gait performance
- pathology that could provoke vertigo or nausea
- uncorrected vision disorders
- contraindications to physical exercise
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Virtual reality headsetAll participants will walk in the three conditions described earlier in this form | Device | Parkinson's Disease patients |
Primary outcome
Long-Range Autocorrelations
Time frame: Change from baseline in long-range autocorrelations during each intervention condition (3 x 10 min walking)
Long-Range Autocorrelations
5 secondary outcomes
Mean gait speed
Time frame: Change from baseline in mean gait speed during each intervention condition (3 x 10 min walking)
Step length
Time frame: Change from baseline in step length during each intervention condition (3 x 10 min walking)
Gait cadence
Time frame: Change from baseline in gait cadence during each intervention condition (3 x 10 min walking)
Coefficient of variation of stride duration
Time frame: Change from baseline in coefficient of variation during each intervention condition (3 x 10 min walking)
Simulator Sickness Questionnaire (SSQ)
Time frame: Change from baseline in SSQ after the VRW condition
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2020.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thierry Lejeune, PhD principal investigator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Virtual reality headset in people with Parkinson Disease and Virtual Reality, run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Long-Range Autocorrelations (time frame: Change from baseline in long-range autocorrelations during each intervention condition (3 x 10 min walking)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2020.